AGIO Agios Pharmaceuticals Inc

Price (delayed)

$34.34

Market cap

$1.95B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.32

Enterprise value

$1.9B

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
The revenue has surged by 55% year-on-year and by 10% since the previous quarter
Agios Pharmaceuticals's gross profit has surged by 55% YoY and by 10% QoQ
AGIO's net income has shrunk by 62% YoY
Agios Pharmaceuticals's EPS has shrunk by 59% YoY

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
56.77M
Market cap
$1.95B
Enterprise value
$1.9B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
65.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.59
Earnings
Revenue
$29.4M
EBIT
-$352.62M
EBITDA
-$335.52M
Free cash flow
-$300.27M
Per share
EPS
-$6.32
Free cash flow per share
-$5.33
Book value per share
$13.24
Revenue per share
$0.52
TBVPS
$15.07
Balance sheet
Total assets
$849.71M
Total liabilities
$105.79M
Debt
$68.35M
Equity
$743.92M
Working capital
$611.94M
Liquidity
Debt to equity
0.09
Current ratio
12.84
Quick ratio
11.64
Net debt/EBITDA
0.15
Margins
EBITDA margin
-1,141.1%
Gross margin
90%
Net margin
-1,199.3%
Operating margin
-1,336.4%
Efficiency
Return on assets
-36.4%
Return on equity
-41.4%
Return on invested capital
-39.3%
Return on capital employed
-44.2%
Return on sales
-1,199.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
-1.89%
1 week
4.06%
1 month
18.29%
1 year
32.18%
YTD
54.2%
QTD
17.44%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$29.4M
Gross profit
$26.45M
Operating income
-$392.95M
Net income
-$352.62M
Gross margin
90%
Net margin
-1,199.3%
AGIO's net income has shrunk by 62% YoY
Agios Pharmaceuticals's operating income has plunged by 61% YoY
The revenue has surged by 55% year-on-year and by 10% since the previous quarter
Agios Pharmaceuticals's gross profit has surged by 55% YoY and by 10% QoQ

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.59
P/S
65.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.59
Agios Pharmaceuticals's EPS has shrunk by 59% YoY
The P/B is 52% above the last 4 quarters average of 1.7 but 11% below the 5-year quarterly average of 2.9
Agios Pharmaceuticals's equity has decreased by 28% YoY and by 8% QoQ
The revenue has surged by 55% year-on-year and by 10% since the previous quarter
AGIO's P/S is 11% above its last 4 quarters average of 59.5

Efficiency

How efficient is Agios Pharmaceuticals business performance
AGIO's return on equity has dropped by 105% year-on-year and by 9% since the previous quarter
The company's return on invested capital has shrunk by 103% YoY and by 9% QoQ
The ROA has plunged by 101% YoY and by 8% from the previous quarter
Agios Pharmaceuticals's return on sales has increased by 9% QoQ but it has decreased by 4.6% YoY

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The quick ratio is down by 29% year-on-year
AGIO's current ratio is down by 27% year-on-year but it is up by 4.6% since the previous quarter
The debt is 91% smaller than the equity
Agios Pharmaceuticals's equity has decreased by 28% YoY and by 8% QoQ
The debt has declined by 17% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.